LH LABCORP HOLDINGS INC.
Services-Medical Laboratories · NYSE · SEC CIK 920148 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6.0%
TTM net income YoY17.4%
TTM EPS YoY19.7%
Revenue 3-yr CAGR6.6%
Net income 3-yr CAGR14.9%
Margins
Gross margin29.0%
Operating margin10.3%
Net margin6.9%
FCF margin8.8%
EBITDA margin15.1%
Returns
ROE11.4%
ROA5.4%
ROIC (approx.)8.6%
Asset turnover0.78x
Leverage & solvency
Liabilities / assets53.2%
Debt / equity0.66x
Current ratio1.41x
Interest coverage6.52x
Cash quality & payout
Operating cash flow / net income1.81x
Accruals ratio-4.4%
Payout ratio23.6%
Capex / revenue3.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.81B | $3.73B | $3.54B | $3.52B | $3.56B | $3.53B | $3.35B | $3.33B |
| Cost of revenue | $2.70B | $2.62B | $2.52B | $2.52B | $2.54B | $2.48B | $2.40B | $2.43B |
| Gross profit | $1.11B | $1.11B | $1.01B | $993.20M | $1.03B | $1.05B | $948.00M | $896.30M |
| SG&A expense | $611.40M | $577.20M | $551.00M | $538.60M | $553.10M | $579.30M | $546.00M | $595.20M |
| Operating income | $402.10M | $451.60M | $380.80M | $267.60M | $396.60M | $394.50M | $326.00M | $216.50M |
| Interest expense | $59.10M | $61.10M | $55.10M | $55.00M | $56.00M | $57.10M | $56.00M | $63.40M |
| Income tax | $64.90M | $87.30M | $41.70M | $25.70M | $75.50M | $66.40M | $62.20M | $40.20M |
| Net income | $262.80M | $298.70M | $277.80M | $164.70M | $261.10M | $237.90M | $212.80M | $143.40M |
| EBITDA | $585.10M | $630.60M | $554.10M | $440.60M | $567.60M | $564.80M | $492.80M | $387.10M |
| EPS (basic) | 3.24 | 3.66 | 3.37 | — | 3.14 | 2.85 | 2.54 | — |
| EPS (diluted) | 3.22 | 3.64 | 3.35 | — | 3.12 | 2.84 | 2.52 | — |
| Dividends declared per share | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 |
| Weighted avg. shares (diluted) | 81.60M | 82.00M | 82.90M | — | 83.70M | 83.90M | 84.30M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $261.80M | $141.80M | $981.10M | $532.30M | $598.10M | $647.30M | $369.40M | $1.52B |
| Receivables | $2.41B | $2.34B | $2.29B | $2.10B | $2.11B | $2.12B | $2.12B | $1.94B |
| Inventory | $538.40M | $562.20M | $497.70M | $534.70M | $521.50M | $508.10M | $488.30M | $493.20M |
| Current assets | $3.97B | $3.81B | $4.56B | $4.02B | $4.08B | $4.09B | $3.79B | $4.81B |
| PP&E, net | $3.14B | $3.10B | $3.07B | $3.08B | $3.11B | $3.13B | $3.09B | $3.05B |
| Goodwill | $7.18B | $7.03B | $6.96B | $6.79B | $6.68B | $6.55B | $6.42B | $6.37B |
| Intangibles | $3.72B | $3.68B | $3.64B | $3.60B | $3.57B | $3.49B | $3.49B | $3.49B |
| Total assets | $18.92B | $18.53B | $19.09B | $18.39B | $18.26B | $18.06B | $17.60B | $18.38B |
| Current liabilities | $2.82B | $2.12B | $2.64B | $2.82B | $2.63B | $2.72B | $2.06B | $3.33B |
| Short-term debt | $601.20M | $900,000 | $500.40M | $500.10M | — | — | — | $1.00B |
| Long-term debt | $5.25B | $5.86B | $5.83B | $5.08B | $5.08B | $5.08B | $5.57B | $5.33B |
| Total debt | $5.85B | $5.86B | $6.33B | $5.58B | $5.08B | $5.08B | $5.57B | $6.33B |
| Total liabilities | $10.06B | $9.91B | $10.34B | $9.76B | $9.55B | $9.57B | $9.28B | $10.31B |
| Shareholders' equity | $8.85B | $8.61B | $8.73B | $8.62B | $8.70B | $8.47B | $8.31B | $8.05B |
| Net debt | $5.59B | $5.72B | $5.35B | $5.05B | $4.48B | $4.43B | $5.20B | $4.81B |
| Shares outstanding | 81.20M | 80.90M | 82.30M | 82.20M | 83.00M | 82.90M | 83.80M | 83.40M |
| Cash flow statement | ||||||||
| Operating cash flow | $563.80M | $445.50M | $191.50M | $614.20M | $387.20M | $620.60M | $18.50M | $777.20M |
| Capital expenditure | $151.60M | $131.60M | $121.00M | $123.90M | $106.70M | $77.90M | $126.00M | $112.10M |
| Free cash flow | $412.20M | $313.90M | $70.50M | $490.30M | $280.50M | $542.70M | -$107.50M | $665.10M |
| Investing cash flow | -$433.70M | -$366.20M | -$322.10M | -$389.90M | -$374.00M | -$94.10M | -$336.00M | -$209.60M |
| Financing cash flow | -$10.00M | -$919.90M | $580.50M | -$290.40M | -$59.50M | -$267.40M | -$839.70M | -$546.70M |
| Depreciation & amortization | $183.00M | $179.00M | $173.30M | $173.00M | $171.00M | $170.30M | $166.80M | $170.60M |
| Stock-based compensation | $30.80M | $34.90M | $31.70M | $29.70M | $29.20M | $34.10M | $32.80M | $27.30M |
| Dividends paid | $58.20M | $58.70M | $61.20M | $59.30M | $59.90M | $59.90M | $61.60M | $60.10M |
| Share buybacks | $0 | $353.80M | $98.00M | $225.00M | $25.00M | $200.00M | $0 | $75.10M |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.